Navigation Links
Nuvelo Announces Publication of NU206 Study Results in,Gastroenterology

ies in animal models of mucositis, where NU206 was shown to diminish symptoms of mucositis, including diarrhea and weight loss.

Scientists from Nuvelo and Kirin worked together to identify and characterize NU206 as part of a collaboration focused on the discovery of novel, secreted proteins. NU206 is the first compound to enter preclinical studies from this program. Nuvelo signed a collaboration agreement with Kirin in April 2005 to develop NU206. Under the agreement, Nuvelo leads worldwide development, manufacturing and commercialization and all operating expenses and profits related to the development and commercialization of NU206 are shared 60% (Nuvelo)/40% (Kirin).

Nuvelo, Inc. is dedicated to improving the lives of patients through the discovery, development and commercialization of novel drugs for acute cardiovascular and cancer therapy. Nuvelo's development pipeline includes three acute cardiovascular programs: alfimeprase, a direct-acting thrombolytic for the treatment of thrombotic-related disorders which is suspended pending review and analysis of clinical data; rNAPc2, an anticoagulant that inhibits the factor VIIa and tissue factor protease complex that completed Phase 2 clinical development in acute coronary syndromes; and preclinical candidate NU172, a direct thrombin inhibitor for use as a short- acting anticoagulant during medical or surgical procedures. Nuvelo is also advancing an emerging oncology pipeline, including rNAPc2 which is in Phase 2 testing for potential use as a cancer therapy, as well as NU206 a preclinical candidate for the potential treatment of chemotherapy/radiation therapy-induced mucositis and inflammatory bowel disease. In addition, Nuvelo expects to leverage its expertise in secreted proteins and cancer antibody discovery to further expand its pipeline and create additional partnering and licensing opportunities.

Information about Nuvelo is available at our website at




Page: 1 2 3 4

Related medicine technology :

1. Nuvelo Announces Presentations on rNAPc2 and NU172 at the XXIst Congress of the International Society on Thrombosis and Haemostasis
2. Nuvelo Announces Publication of Phase 2 rNAPc2 Study Results in Journal of American College of Cardiology
3. Nuvelo Announces Publication of Preclinical Study Results Demonstrating the Potential of NTB-A as a New Target for Leukemia and Lymphomas
4. Nuvelo Announces Presentation on NU206 at 2007 American Association for Cancer Research Annual Meeting
5. Nuvelo Announces Presentation on rNAPc2 at American College of Cardiology 56th Annual Scientific Session
6. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
7. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
8. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
9. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
10. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
11. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
Post Your Comments:
(Date:9/16/2014)... BRIDGEWATER, N.J. , Sept. 16, 2014 /PRNewswire/ ... pharmaceutical company focused on developing and commercializing therapeutic ... renal and infectious diseases, announces the amendment and ... and E preferred stock and related warrants, as ... 2014 common stock and warrant financing, to remove ...
(Date:9/16/2014)... Sept. 16, 2014  Relmada Therapeutics, Inc., (OTCBB: RLMD), ... of chronic pain, announced today that it has entered ... (MSKCC) in a series of animal studies for levorphanol, ... extended release form of levorphanol.  Gavril Pasternak, MD, PhD, ... Dr. Pasternak said, "Levorphanol is a ...
(Date:9/15/2014)... , Sept. 16, 2014 The French ... (HNF) announced today an agreement to collaborate on programs ... support the development of a stronger CMT patient and ... support to several HNF,s initiatives including: , ... the HNF website featuring  HNF newsletters, materials and latest ...
Breaking Medicine Technology:CorMedix Amends and Restates Outstanding Securities to Remove Provisions Causing Derivative Liability Classification 2CorMedix Amends and Restates Outstanding Securities to Remove Provisions Causing Derivative Liability Classification 3Relmada Therapeutics Enters Into Agreement with Memorial Sloan Kettering to Better Clarify Unique Mechanism of Action for LevoCap ER 2Relmada Therapeutics Enters Into Agreement with Memorial Sloan Kettering to Better Clarify Unique Mechanism of Action for LevoCap ER 3Pharnext and the Hereditary Neuropathy Foundation Collaborate to Increase Awareness of Charcot-Marie-Tooth Disease 2Pharnext and the Hereditary Neuropathy Foundation Collaborate to Increase Awareness of Charcot-Marie-Tooth Disease 3Pharnext and the Hereditary Neuropathy Foundation Collaborate to Increase Awareness of Charcot-Marie-Tooth Disease 4
(Date:9/16/2014)... Tara Haelle ... News) -- About 14.5 million U.S. cancer survivors are ... the American Association for Cancer Research reported Tuesday. ... and include nearly 380,000 survivors of childhood cancer, according ... advances in prevention, identification, research and treatment of cancer ...
(Date:9/16/2014)... New York (PRWEB) September 16, 2014 ... ) filed against C.R. Bard, Inc. continue to ... in U.S. District Court, Southern District of West ... Order dated September 15, 2014, the Court has ... beneficial to the proceeding. The Order indicates that ...
(Date:9/16/2014)... Danny Dreyer, ChiRunning & ChiWalking founder ... events throughout the U.S. Dreyer is one of the ... taught a full circuit of nationwide workshops since 2004. ... tracks at his workshops so participants of all levels ... techniques. , Workshop schedule: , ,     September ...
(Date:9/16/2014)... One in five American men admits to using ... survey shows. A nationally representative study from ... is more prevalent than diabetes. This violence includes ... hitting, kicking, biting, choking, burning or threatening their ... Although abuse by high-profile professional athletes has recently ...
(Date:9/16/2014)... The Wistar Institute,s Meenhard Herlyn, D.V.M., D.Sc., is ... Program of Research Excellence (SPORE) grant, a prestigious ... researchers at Wistar and the University of Pennsylvania ... this SPORE is to translate fundamental laboratory discoveries ... melanoma and other skin cancers. , Melanoma is ...
Breaking Medicine News(10 mins):Health News:Targeted Drugs Among Successes Against Cancer, Says New Report 2Health News:Targeted Drugs Among Successes Against Cancer, Says New Report 3Health News:Targeted Drugs Among Successes Against Cancer, Says New Report 4Health News:Vaginal Mesh Lawsuit News: Discovery Conferences Scheduled for Federal Transvaginal Mesh Lawsuits Filed Against C.R. Bard, Bernstein Liebhard LLP Reports 2Health News:Vaginal Mesh Lawsuit News: Discovery Conferences Scheduled for Federal Transvaginal Mesh Lawsuits Filed Against C.R. Bard, Bernstein Liebhard LLP Reports 3Health News:Vaginal Mesh Lawsuit News: Discovery Conferences Scheduled for Federal Transvaginal Mesh Lawsuits Filed Against C.R. Bard, Bernstein Liebhard LLP Reports 4Health News:Join ChiRunning® Founder, Danny Dreyer, on Fall 2014 US Workshop 2Health News:Join ChiRunning® Founder, Danny Dreyer, on Fall 2014 US Workshop 3Health News:1 in 5 U.S. Men Admits to Violence Against Spouse, Partner 2Health News:Wistar and Penn Medicine collaborate on $12.1 million SPORE grant in melanoma 2Health News:Wistar and Penn Medicine collaborate on $12.1 million SPORE grant in melanoma 3
... disturbing implications for the government, pension companies and life ... warning that increases in longevity translate into bad news ... look after us when we are old; to make ... uncertain. , Kevin Dowd, Professor of Financial Risk Management ...
... 29th 2007 With the genomic revolution radical improvement ... cancer. This is of the utmost importance, since the ... detection. In a special issue of Disease Markers, published ... the identification and understanding of biomarkers for epithelial ovarian ...
... found incidentally during a CT scan, and the masses ... according to a recent study conducted by researchers at ... increased utilization of CT, we are frequently encountering findings ... scanned, the so called incidentalomas, of which adrenal masses ...
... winning program at the Best Practices in Consumer ... 25-26, 2008, WASHINGTON, Nov. 29 Today ... selected the finalists for its,inaugural Best Practices in ... attracted entries detailing,innovative and proven programs that are ...
... Revolutionary new intimacy creme aids women in greater ... Passion Parties, Inc. is excited to,add the new ... cornerstone of the Passion Parties product line complete ... the G-Spot Creme instills a,positive level of confident ...
... Signs contract with Best Medical International Inc., ... leading,provider of medical isotopes and radiopharmaceuticals, today signed ... its external beam,therapy and self-contained irradiator product lines. ... growth strategy to focus its resources on being ...
Cached Medicine News:Health News:URAC Names Medco as a Finalist in First-ever Best Practices in Consumer Empowerment and Protection Awards 2Health News:URAC Names Medco as a Finalist in First-ever Best Practices in Consumer Empowerment and Protection Awards 3Health News:Passion Parties Hits the Spot 2Health News:MDS Nordion Divests Non Strategic Product Lines 2
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: